SE0200356D0 - Novel use - Google Patents

Novel use

Info

Publication number
SE0200356D0
SE0200356D0 SE0200356A SE0200356A SE0200356D0 SE 0200356 D0 SE0200356 D0 SE 0200356D0 SE 0200356 A SE0200356 A SE 0200356A SE 0200356 A SE0200356 A SE 0200356A SE 0200356 D0 SE0200356 D0 SE 0200356D0
Authority
SE
Sweden
Prior art keywords
sub
novel use
quinazolinfyl
pgd
quinolin
Prior art date
Application number
SE0200356A
Other languages
English (en)
Inventor
Simon Teague
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0200356A priority Critical patent/SE0200356D0/sv
Publication of SE0200356D0 publication Critical patent/SE0200356D0/sv
Priority to AU2003206310A priority patent/AU2003206310A1/en
Priority to PCT/SE2003/000184 priority patent/WO2003066046A1/en
Priority to EP03703600A priority patent/EP1474136A1/en
Priority to JP2003565470A priority patent/JP2005521675A/ja
Priority to US10/503,708 priority patent/US20050165033A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0200356A 2002-02-05 2002-02-05 Novel use SE0200356D0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE0200356A SE0200356D0 (sv) 2002-02-05 2002-02-05 Novel use
AU2003206310A AU2003206310A1 (en) 2002-02-05 2003-02-04 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
PCT/SE2003/000184 WO2003066046A1 (en) 2002-02-05 2003-02-04 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
EP03703600A EP1474136A1 (en) 2002-02-05 2003-02-04 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
JP2003565470A JP2005521675A (ja) 2002-02-05 2003-02-04 喘息、ｃｏｐｄおよび他の疾患の治療におけるインドール−３−酢酸の使用
US10/503,708 US20050165033A1 (en) 2002-02-05 2003-02-04 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200356A SE0200356D0 (sv) 2002-02-05 2002-02-05 Novel use

Publications (1)

Publication Number Publication Date
SE0200356D0 true SE0200356D0 (sv) 2002-02-05

Family

ID=20286889

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0200356A SE0200356D0 (sv) 2002-02-05 2002-02-05 Novel use

Country Status (6)

Country Link
US (1) US20050165033A1 (sv)
EP (1) EP1474136A1 (sv)
JP (1) JP2005521675A (sv)
AU (1) AU2003206310A1 (sv)
SE (1) SE0200356D0 (sv)
WO (1) WO2003066046A1 (sv)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362756A1 (en) * 2001-10-10 2003-04-22 Millennium Pharmaceuticals, Inc. 21132, a human g-protein coupled receptor family member and uses therefor
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
CA2511214C (en) 2002-12-20 2012-12-18 Tularik, Inc. Asthma and allergic inflammation modulators
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
US7205329B2 (en) 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB2407318A (en) * 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
DE602005006539D1 (de) 2004-03-11 2008-06-19 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivate
US8022063B2 (en) 2004-05-29 2011-09-20 7Tm Pharma A/S CRTH2 receptor ligands for medicinal uses
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP1805171A4 (en) 2004-09-21 2009-05-13 Wyeth Corp CRTH2 RECEPTOR ANTAGONISM DISPLAYING INDIGENOUS ACIDS AND APPLICATIONS THEREOF
WO2006068162A1 (ja) * 2004-12-24 2006-06-29 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の治療剤
PL1833791T3 (pl) 2004-12-27 2011-12-30 Actelion Pharmaceuticals Ltd Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
UA90145C2 (ru) * 2005-05-24 2010-04-12 Лаборатуар Сероно С.А. Трициклические спиро-производные как модуляторы crth2
EP1932839A4 (en) 2005-09-06 2014-09-10 Shionogi & Co INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR
DK1928457T3 (da) * 2005-09-30 2013-02-04 Pulmagen Therapeutics Asthma Ltd Quinoliner og deres terapeutiske anvendelse
GB0519969D0 (en) * 2005-09-30 2005-11-09 Argenta Discovery Ltd Quinoline compounds
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525141D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
WO2007138282A2 (en) 2006-05-26 2007-12-06 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
WO2007149312A2 (en) 2006-06-16 2007-12-27 The Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
AU2007279079A1 (en) 2006-07-22 2008-01-31 Oxagen Limited Compounds having CRTH2 antagonist activity
PT2051962E (pt) 2006-08-07 2012-01-10 Actelion Pharmaceuticals Ltd Derivados do ácido (3-amino-1,2,3,4-tetrahidro-9hcarbazol- 9-il)-acético
PT2229358E (pt) 2007-12-14 2011-06-29 Pulmagen Therapeutics Asthma Ltd Indoles e sua utilização terapêutica
US8183293B2 (en) 2007-12-19 2012-05-22 Amgen Inc. Phenyl acetic acid derivatives
SI2250161T1 (sl) 2008-01-18 2014-04-30 Atopix Therapeutics Limited Spojine, ki imajo aktivnost crth2 antagonista
JP2011509990A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
US9180114B2 (en) * 2008-11-26 2015-11-10 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
WO2011055270A1 (en) 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
BR112012017756A2 (pt) 2009-12-23 2016-04-19 Ironwood Pharmaceuticals Inc moduladores crth2
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
NZ603108A (en) 2010-03-22 2014-05-30 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
CN107021951B (zh) 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC刺激物
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN103402515B (zh) 2010-11-09 2017-05-17 铁木医药有限公司 sGC刺激剂
HUE028972T2 (en) 2011-04-14 2017-01-30 Actelion Pharmaceuticals Ltd 7- (Heteroarylamino) -6,7,8,9-tetrahydropyrido [1,2-a] indole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
EP2548863A1 (en) * 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
KR102205774B1 (ko) 2012-03-21 2021-01-20 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 모발 성장을 조절하는 방법 및 조성물
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
SI3660013T1 (sl) 2013-03-15 2022-05-31 Cyclerion Therapeutics, Inc. SGC stimulatorji
WO2015089182A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
CN106103435B (zh) 2014-03-17 2018-11-16 爱杜西亚药品有限公司 氮杂吲哚乙酸衍生物及彼等作为前列腺素d2受体调节剂的用途
MX2016011900A (es) 2014-03-18 2016-12-05 Actelion Pharmaceuticals Ltd Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN107406422B (zh) 2014-09-17 2022-02-01 赛科理音医疗有限公司 作为sGC刺激剂的吡唑衍生物
AU2015317823A1 (en) 2014-09-17 2017-03-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
EP4420734A3 (en) 2015-02-13 2024-11-06 Institut National de la Santé et de la Recherche Médicale Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
MX2018001217A (es) 2015-07-30 2018-09-12 Univ Pennsylvania Alelos polimorficos de nucleotidos individuales del gen humano dp-2 para la deteccion de la susceptibilidad a la inhibicion del crecimiento del cabello por pgd2.
PL3350179T3 (pl) 2015-09-15 2021-08-02 Idorsia Pharmaceuticals Ltd Krystaliczne postacie
CA3029374A1 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Phosphorus prodrugs of sgc stimulators
AU2017292818B2 (en) 2016-07-07 2021-10-21 Cyclerion Therapeutics, Inc. Solid forms of an sGC stimulator
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US20190183812A1 (en) * 2017-12-14 2019-06-20 Nmd Pharma A/S Compounds For The Treatment Of Neuromuscular Disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
CN113425714B (zh) * 2021-08-04 2022-04-26 华南师范大学 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) * 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB1407658A (en) * 1973-03-06 1975-09-24 Ici Ltd Process for the manufacture of indole derivatives
GB1460348A (en) * 1974-02-04 1977-01-06 Ici Ltd Quinazoline derivativesa
EP0499143B1 (en) * 1991-02-09 1999-05-06 B.S.D. BIO SCIENCE DEVELOPMENT SNC Di OMINI C. & ZUCCARI G. Anti-reactive anti-asthmatic activity of acetylsalicylic acid by inhalation
US5965582A (en) * 1994-08-03 1999-10-12 Asta Medica Aktiengesellschaft N-benzylindole and benzopyrazole derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunemodulating effect
JP2000297037A (ja) * 1999-04-15 2000-10-24 Yosuke Tanabe 乾癬治療剤
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2

Also Published As

Publication number Publication date
AU2003206310A1 (en) 2003-09-02
EP1474136A1 (en) 2004-11-10
US20050165033A1 (en) 2005-07-28
JP2005521675A (ja) 2005-07-21
WO2003066046A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
SE0200356D0 (sv) Novel use
WO2004045618A3 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
MXPA02011311A (es) Composicion novedosa.
SE0200411D0 (sv) Novel use
EA200200739A1 (ru) Пиримидинкарбоксамиды, используемые в качестве ингибиторов изосимов pde4
NO20052591D0 (no) Pyridopyrolizin og pyridoindolizinderivater
NO20061254L (no) Farmasoytiske blandinger
DE60215000D1 (de) DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
UA81635C2 (en) 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12.
EA200601141A1 (ru) Сульфонамидные производные для лечения заболеваний
ATE402141T1 (de) Phenäthanolaminderivate zur behandlung von krankheiten der atemwege
DK1718336T3 (da) Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
NO20081480L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
NZ547523A (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
MY142773A (en) Substituted 4-alkyl-and-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
NI200700039A (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38.
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
MXPA04007294A (es) Composicion para inhalacion.
NO20006665D0 (no) Substituert ß-diketoner og deres anvendelse
WO2005007134A8 (de) Pulverformulierungen für die inhalation enthaltend ein neues anticholinergikum
SE0402972D0 (sv) Novel compounds
CY1113392T1 (el) Νεες κρυσταλλικες μορφες του βρωμιουχου τιοτροπιου